AstraZeneca Signs $150 Million China Deal with Ironwood Pharma

AstraZeneca signed a $150 million deal with Ironwood Pharmaceuticals to co-develop and co-commercialize Ironwood's novel constipation treatment in China. Linaclotide, a guanylate cyclase-C (GC-C) agonist, was approved by the US FDA in August to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. In May, Ironwood announced a Phase III trial of the drug in China. More details.... Stock Symbols: (NYSE: AZN) (NSDQ: IRWD) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});